Listed

Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 9, 2021 and accepted by EDGAR at Nov 8, 2021, 20:23 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$28.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$92.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2021-07-01 to 2021-09-30$9.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$29.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-01 to 2021-09-30$24.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$75.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30−$19.6mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$56.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$968.0kus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$2.8mus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30−$1.4mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30−$3.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30−$13.8mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$49.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30−$0.18us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30−$0.66us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30−$0.18us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30−$0.66us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3076,301,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3075,494,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30−$37.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$12.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$29.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$73.5mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$282.2mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$47.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$182.9mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$99.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001162194-21-000087. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.